[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338190-105":59,"doc-detail-338190-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bcl2-expression-is-enriched-in-advanced-prostate-cancer-with-features-of-lineage-plasticity","BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity","","BCL2 expression is enriched in AR-negative metastatic castration-resistant prostate cancer (mCRPC), where it links to shorter overall survival and resistance to androgen receptor signaling inhibitors. High BCL2 levels associate with lineage plasticity features and neuroendocrine marker positivity. The study shows BCL2 regulation by DNA methylation, connections to epithelial-mesenchymal transition, and upregulation by the neuronal transcription factor ASCL1. BCL2 inhibition produces antitumor effects in only subsets of BCL2-positive models, supporting combination strategies to enhance apoptosis and improve response.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bcl2-expression-is-enriched-in-advanced-prostate-cancer-with-features-of-lineage-plasticity/338190/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bcl2-expression-is-enriched-in-advanced-prostate-cancer-with-features-of-lineage-plasticity/338190.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical gap does the study address regarding BCL2 in metastatic CRPC?","Question",{"text":112,"@type":113},"It aims to characterize BCL2 expression in metastatic CRPC, determine its association with AR expression, elucidate regulatory mechanisms, and assess BCL2 as a therapeutic target and/or biomarker with clinical utility.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is BCL2 expression related to treatment resistance in metastatic CRPC?",{"text":117,"@type":113},"BCL2 expression is enriched in AR-negative mCRPC and associates with shorter overall survival and resistance to androgen receptor signaling inhibitors.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanisms regulate BCL2 expression and what role does ASCL1 play?",{"text":121,"@type":113},"BCL2 expression is regulated by DNA methylation, is associated with epithelial-mesenchymal transition, and is increased by the neuronal transcription factor ASCL1.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338190,1790182579,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nBCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity  \nDaniel Westaby,1,2 Juan M. Jiménez-Vacas,1 Ines Figueiredo,1 Jan Rekowski,1 Claire Pettinger,2 Bora Gurel,1 Arian Lundberg,1 Denisa Bogdan,1 Lorenzo Buroni,1 Antje Neeb,1 Ana Padilha,1 Joe Taylor,1 Wanting Zeng,1 Souvik Das,1 Emily Hobern,1  \nRuth Riisnaes,1 Mateus Crespo,1 Susana Miranda,1 Ana Ferreira,1 Brian P. Hanratty,3 Daniel Nava Rodrigues,1 Claudia Bertan,1 George Seed,1 Maria de Los Dolores Fenor de La Maza,1,2 Christina Guo,1,2 Juliet Carmichael,1,2 Rafael Grochot,1,2 Khobe Chandran,1,2 Anastasia Stavridi,4 Andreas Varkaris,4 Nataly Stylianou,5 Brett G. Hollier,5 Nina Tunariu,1,2 Steven P. Balk,4 Suzanne Carreira,1 Wei Yuan,1 Peter S. Nelson,3,6 Eva Corey,6 Michael Haffner,3,6 Johann de Bono,1,2 and Adam Sharp1,2  \n1The Institute of Cancer Research, London, United Kingdom. 2The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. 3Fred Hutchinson Cancer Center, Seattle, Washington, USA. 4Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. 5Australian Prostate Cancer Research Centre–Queensland, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia. 6University of Washington, Seattle, Washington, USA.  \nThe widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of ARindependent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage plasticity, and transformation to prostate cancers (PCs) that exhibit phenotypes of neuroendocrine or basal-like cells. The anti-apoptotic protein BCL2 is upregulated in neuroendocrine cancers and may be a therapeutic target for this aggressive PC disease subset. There is an unmet clinical need, therefore, to clinically characterize BCL2 expression in metastatic CRPC (mCRPC), determine its association with AR expression, uncover its mechanisms of regulation, and evaluate BCL2 as a therapeutic target and/ or biomarker with clinical utility. Here, using multiple PC biopsy cohorts and models, we demonstrate that BCL2 expression is enriched in AR-negative mCRPC, associating with shorter overall survival and resistance to ARSIs. Moreover, high BCL2 expression associates with lineage plasticity features and neuroendocrine marker positivity. We provide evidence that BCL2 expression is regulated by DNA methylation, associated with epithelial-mesenchymal transition, and increased by the neuronal transcription factor ASCL1. Finally, BCL2 inhibition had antitumor activity in some, but not all, BCL2-positive PC models, highlighting the need for combination strategies to enhance tumor cell apoptosis and enrich response.  \nIntroduction  \nProstate cancer (PC) is the most frequently diagnosed malerelated cancer in the Western world (1) . In Europe, 1% of all men die from this disease (1, 2). PC is largely driven by the androgen receptor (AR), and androgen deprivation therapy (ADT) is the cornerstone of treatment for advanced disease (3, 4). However, ADT resistance invariably occurs, and tumors progress from castration-sensitive PC (CSPC) to castration-resistant PC (CRPC) (5). Metastatic CRPC (mCRPC) is a lethal malignancy with an over-  \nall survival (OS) of 2–3 years (6, 7). Although next-generation AR signaling inhibitors (ARSIs) improve OS in metastatic CSPC and CRPC, the tumors inevitably develop resistance (5) .  \nMost commonly, treatment resistance is driven by reactivation of AR signaling (5) . However, intensive selective pressure from the use of ARSIs has resulted in an increasing emergence of PCs that adapt to survive without AR signaling, often with loss of AR expression, lineage plasticity, and transformation to PCs that exhibit phenotypes of neuroendocrine or basal-like cells (5, 8–10) .  \nAuthorship note: DW, JMJV, and IF co","cbCainz4SCDEPz3f","https://ap.wps.com/l/cbCainz4SCDEPz3f","pdf",19570929,15,"English","# Introduction\n## Androgen receptor signaling inhibitors and resistance\n## Lineage plasticity and neuroendocrine/basal-like phenotypes\n## Authorship and conflict of interest","[{\"question\":\"What clinical gap does the study address regarding BCL2 in metastatic CRPC?\",\"answer\":\"It aims to characterize BCL2 expression in metastatic CRPC, determine its association with AR expression, elucidate regulatory mechanisms, and assess BCL2 as a therapeutic target and/or biomarker with clinical utility.\"},{\"question\":\"How is BCL2 expression related to treatment resistance in metastatic CRPC?\",\"answer\":\"BCL2 expression is enriched in AR-negative mCRPC and associates with shorter overall survival and resistance to androgen receptor signaling inhibitors.\"},{\"question\":\"What mechanisms regulate BCL2 expression and what role does ASCL1 play?\",\"answer\":\"BCL2 expression is regulated by DNA methylation, is associated with epithelial-mesenchymal transition, and is increased by the neuronal transcription factor ASCL1.\"}]","BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity | PDF",1790022430,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cde563f3fe5d5fc313119882ab271118.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c8d17c72141b8e1037f72d7567efcfa.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69854eca9ba17e66eaec41273c53d69e.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a39e95b833b12353583cacacd94f8e46.webp",980,1311]